Page 125 - Eceptor News Today

Researchers performed an unbiased evaluation of the early memory B cell repertoire specific for the Omicron and Delta variants of SARS-CoV-2.

In this interview, News-Medical speaks to Anand Patel and Michael Dyer from St. Jude's Children's Research Hospital about their recent research suggesting EGFR inhibitors may prevent rhabdomyosarcoma recurrence.

A new study analyzed the imprinted antibody responses towards the SARS-CoV-2 Omicron subvariants.

In a recent study published in the journal Molecular Therapy, researchers identified Bifonazole, an imidazole-based antifungal agent, to have potent activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using high-throughput screening of small molecules.

In a recent study posted to the bioRxiv* preprint server, researchers reported that nanoparticles could prevent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) cell entry.

In a recent study posted to the medRxiv* preprint server, researchers applied deep learning methods and identified genetic variants linked to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-caused mortality.

In a recent study posted to the bioRxiv* preprint server, researchers assessed the impact of coronavirus disease 2019 (COVID-19) on antibody-mediated immunity.

A new study explored key vaccine features which could help induce and preserve humoral immunity against SARS-CoV-2 infection.

A receptor that was first identified as necessary for insulin action, that also is located on the neural stem cells found deep in the brains of mice, is pivotal for brain stem cell longevity, according to a Rutgers study, a finding that has important implications for brain health and future therapies for brain disorders.

A study recently published in the journal Cell Host & Microbe has described that all three sublineages of the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit similar host cell entry efficiency and are neutralized equally by antibodies generated in response to coronavirus disease 2019 (COVID-19) booster vaccination